Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

Description: It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.

There are several promising vaccines: the prophylactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis.

In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

- Melanoma Vaccines
- Lung Cancer Vaccines
- Prostate Cancer Vaccines
- Cervical Cancer Vaccines
- Brain Cancer Vaccines
- Colon/Rectal Cancer Vaccines
- Breast Cancer Vaccines
- Lymphoma Vaccines
- Ovarian Cancer Vaccines
- Leukemia Vaccines
- Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:
- Forecasts for Future Revenues from Cancer Vaccines
- Cancer Epidemiology
- Reviews of Products in the Pipeline
- Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
- Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines, the following companies are profiled in this report:

- Antigenics, Inc.
- Avax Technologies, Inc.
- Biovest International, Inc.
- Cell Genesys, Inc.
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
## TABLE OF CONTENTS

**CHAPTER ONE: EXECUTIVE SUMMARY**
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors

**CHAPTER TWO: INTRODUCTION**
- Introduction
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
  - Antigen/Adjuvant Vaccines
  - Whole Cell Tumor Vaccines
  - Dendritic Cell (DC) Vaccines
  - Viral Vectors and DNA Vaccines
  - Idiotype Vaccines
- Types of Therapeutic Vaccines
  - Patient-Specific Vaccines
  - Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART-1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
- Growing and Aging Population
- Life Expectancy and Cancer

**CHAPTER THREE: CERVICAL CANCER VACCINES**
- Overview
- Description of Vaccines on the Market
  - Gardasil/Silgard
  - Cervarix
- Description of Vaccines in Development
  - TG 4001/R3484
  - HspE7
  - Lovaxin C
  - VGX-3100
  - CA-9
- Market Summary
  - Current and Potential Competitors and Analysis, 2012

**CHAPTER FOUR: COLON/RECTAL CANCER VACCINES**
- Overview
- Description of Vaccines on the Market
  - OncoVAX
- Description of Vaccines in Development
  - OncoVAX
  - TroVAX
  - Avicine
CEA VRP Vaccine
Collidem
IMA910
Lapuleucel-T
Oncophage
CDX-1307-01
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2012

CHAPTER FIVE: LUNG CANCER VACCINES
Overview
Description of Vaccines in Development
Lucanix
MAGE-A3 Peptide
Stimuvax
EGF Cancer Vaccine
GV-1001
HyperAcute Lung
IDM 2101 (EP-2101)
Oncophage
INGN 225
TG 4010
LungVAX
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
DC Vax
LS23S
Market Summary
Potential Competitors and Analysis, 2012

CHAPTER SIX: LYMPHOMA VACCINES
Overview
Description of Vaccines in Development
MyVax
BiovaxID
Favld
TG 1042
Market Summary
Potential Competitors and Analysis, 2012

CHAPTER SEVEN: MELANOMA VACCINES
Overview
Description of Vaccines on the Market
Description of Vaccines in Development
M-VAX
GMK
Allovectin-7
MDX-1379 with Combination Treatment MDX-010
Oncophage
MAGE-A3 ASCI 3
Uvidem
AGI-101H Vaccine
ALVAC Vaccine
HyperAcute Melanoma
Market Summary
Potential Competitors and Analysis, 2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES
Overview
Description of Vaccines in Development
Provenge
DCVax-Prostate
CHAPTER NINE: BREAST CANCER VACCINES
Overview
Description of Vaccines in Development
INGN 225
CEA VRP Vaccine
MVA-BN HER2
Lapuleucel-T
PX 104.1
CDX-1307-02
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP
Market Summary

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Overview
Description of Vaccines in Development
GV 1001
GI-4000
Avicine
GVAX
HyperAcute Pancreas
Oncophage
CDX-1307-01
CRS-100
CRS-207
DC Vax
MKC1106-PP
Market Summary

CHAPTER ELEVEN: RENAL CANCER VACCINES
Overview
Description of Vaccines on the Market
Oncophage
Description of Vaccines in Development
Oncophage
Reniale
TroVAX
IMA901
AGS-003
MDX-1106
MKC1106-PP
Market Summary
Potential Competitors and Analysis, 2012

CHAPTER TWELVE: BRAIN CANCER VACCINES
Overview
Glioblastoma
Neuroblastoma
Description of Vaccines in Development
DCVax-Brain
CDX-110
GliAtak
Oncophage
CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Overview
Description of Vaccines on the Market
BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)
Description of Vaccines in Development
Bexidem
CG0070
MDX-1307-01

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Overview
Description of Vaccines in Development
OVax Autologous Cell Vaccine
Lapuleucel-T
Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
MKC1106-PP

CHAPTER FIFTEEN: LEUKEMIA VACCINES
Overview
Description of Vaccines in Development
GVAX
PR1 Peptide Vaccine
AGS-005

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
New Genetic Technique
Future Growth in Vaccines

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
Overview
Total Market Size and Forecast
Market and Competitor Analysis

CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES
Introduction
Antigenics, Inc
Avax Technologies, Inc
Biovest International, Inc
Cell Genesys, Inc
Dendreon Corporation
Genitope Corporation
GlaxoSmithKline plc
Merck & Company, Inc
Northwest Biotherapeutics, Inc
NovaRx
Oncothryeon
Vaccinogen
Vical, Inc
CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012

CHAPTER TWO: INTRODUCTION
Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
Figure 2-2: Total Cancer Incidence by Sex and Country
Table 2-3: World Population by Selected Geographical Region, 2007-2050
Figure 2-4: World Population by Selected Geographical Region, 2007-2050
Table 2-4: Estimated World Population by Age and Geographical Region, 2007
Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
Table 2-5: Percent Population Over 65 by Year and Region
Figure 2-5: Estimated World Population by Age, 2007 and 2050
Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
Table 2-7: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

CHAPTER THREE: CERVICAL CANCER VACCINES
Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
Figure 3-2: Cervical Cancer Vaccine Market, 2008-2012
Table 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
Table 3-3: Cervical Cancer Vaccines Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 3-3: Cervical Cancer Vaccines Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES
Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
Figure 4-2: Colon/Rectal Cancer Vaccine Market, 2008-2012
Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
Figure 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012

CHAPTER FIVE: LUNG CANCER VACCINES
Table 5-1: Types of Primary Lung Cancer
Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
Table 5-3: Lung Cancer Vaccines in the Pipeline

CHAPTER SIX: LYMPHOMA VACCINES
Table 6-1: Classification of Non-Hodgkin's Lymphomas
Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
Table 6-3: Lymphoma Vaccines in the Pipeline
Figure 6-2: Lymphoma Vaccine Market, 2008-2012
Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012

CHAPTER SEVEN: MELANOMA VACCINES
Table 7-1: Malignant Conditions of the Skin
Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
Table 7-3: Melanoma Vaccines in the Pipeline
Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 7-4: Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES
Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
Table 8-2: Prostate Cancer Vaccines in the Pipeline
Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012

CHAPTER NINE: BREAST CANCER VACCINES
Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
Table 9-2: Breast Cancer Vaccines in the Pipeline

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES
Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline

CHAPTER ELEVEN: RENAL CANCER VACCINES
Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
Table 11-2: Renal Cancer Vaccines in the Pipeline
Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012

CHAPTER TWELVE: BRAIN CANCER VACCINES
Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
Table 12-2: Brain Cancer Vaccines in the Pipeline

CHAPTER THIRTEEN: BLADDER CANCER VACCINES
Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
Table 13-2: Bladder Cancer Vaccines in the Pipeline

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES
Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
Table 14-2: Ovarian Cancer Vaccines in the Pipeline

CHAPTER FIFTEEN: LEUKEMIA VACCINES
Table 15-1: TYPES OF LEUKEMIA
Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
Table 15-3: Leukemia Vaccines in the Pipeline

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET
Table 16-1: Cancer Detection Tests

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS
Table 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012

CANCER VACCINE CORPORATE PROFILES

COMPANY NAMES AND ADDRESSES

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2860885/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition
Web Address: http://www.researchandmarkets.com/reports/2860885/
Office Code: SCD2STWK

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3995</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 4395 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7990</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name:  ____________________________  Last Name:  ____________________________
Email Address:  *  ____________________________
Job Title:  ____________________________
Organisation:  ____________________________
Address:  ____________________________
City:  ____________________________
Postal / Zip Code:  ____________________________
Country:  ____________________________
Phone Number:  ____________________________
Fax Number:  ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World